Neuraxis Inc(NRXS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.78 | Insider Own | 31.94% | Shs Outstand | 12.5M | Perf Week | -3.65% |
| Market Cap | 0.09B | Forward P/E | - | EPS next Y | 64.47% | Insider Trans | 0.06% | Shs Float | 8.6M | Perf Month | -0.56% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.21 | Inst Own | 23.02% | Short Float | 4.83% | Perf Quarter | 8.19% |
| Income | -0.01B | P/S | 16.83 | EPS this Y | 20% | Inst Trans | 8.18% | Short Ratio | 3.22 | Perf Half Y | -11.76% |
| Sales | 0.01B | P/B | 13.21 | EPS next 5Y | - | ROA | -89.89% | Short Interest | 0.41M | Perf YTD | 57.05% |
| Book/sh | 0.54 | P/C | 10.76 | EPS past 3/5Y | -1.64% -6.18% | ROE | -139.76% | 52W High | -23.58% ($9.33) | Perf Year | 155.56% |
| Cash/sh | 0.66 | P/FCF | - | Sales past 3/5Y | 9.96% 13.08% | ROIC | -111.29% | 52W Low | 222.62% ($2.21) | Perf 3Y | 234.74% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.92% | Gross Margin | 85.55% | Volatility(W/M) | 4.85% 6.11% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 15.32 | Sales Y/Y TTM | 65.22% | Oper. Margin | -144.51% | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.95 | EPS Q/Q | 15.63% | Profit Margin | -159.01% | RSI (14) | 47.99 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | Sales Q/Q | 115.72% | SMA20 | -1.72% ($7.25) | Beta | 1.37 | Target Price | $13 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/11/9 | SMA50 | 4.33% ($6.83) | Rel Volume | 1.17 | Prev Close | $7.55 |
| Employees | 24 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 40.62% -3.56% | SMA200 | 6.95% ($6.67) | Avg Volume(3M) | 0.13M | Price | $7.13 |
| IPO | 2023/8/9 | Option/Short | Yes/Yes | Trades | 402 | Volume | 150,396 | Change | -5.56% |
🩺 This is a US medical technology company that develops and supplies neuromodulation therapeutic devices targeting functional abdominal pain in children and adolescents. The company has commercialized its flagship product, the IB-Stim, which uses percutaneous electrical nerve stimulation targeting nerves around the ear, and operates a business specialized in the pediatric gastrointestinal space through a non-invasive, drug-free treatment approach.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded about as much as usual. That is 117% of its average volume.
Next earnings report: November 9
8 days to go.
NRXS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,683. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +234.7%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 23.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #369 of 597 in the industry
Based on market cap of $90M.
FAQ
What kind of company is NRXS?
NRXS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NRXS?
The market cap of NRXS is approximately $90M, ranking 4,526 within its sector.
What is the 52-week high and low for NRXS?
NRXS has recorded a 52-week high of $9.33 and a low of $2.21.
